Innovators in Parkin therapeutics.
NysnoBio has unparalleled depth of expertise to deliver on the promise of the therapeutic potential of the Parkin protein. Our team members:
were the first to identify the Parkin gene linked to Parkinsons’s Disease,
were first to demonstrate Parkin is an E3 ubiquitin ligase,
were first to publish a crystal structure demonstrating key aspects of enzymology,
have greater than 20 years expertise in gene therapy using AAV,
and have clinical neuroimaging expertise, ensuring definitive results in the clinic.
LEADERSHIP
Jennifer A. Johnston, PhD
Cofounder and CEO
David M. Weiner, MD
Chief Medical Officer
Elizabeth Higgins, PhD
Chief Technology Officer
Christina Gamba-Vitalo, PhD
Head of in vivo Pharmacology and Toxicology
Ron Mandel, PhD
Head of Gene Therapy Programs
Sarah Finley
Project Management
David Giannini
Cofounder and Executive Chairman
SCIENTIFIC ADVISORY BOARD
Andres M. Lozano, OC, MD, PhD, FRCSC, FRSC, FCAHS
Neurosurgeon, Krembil Neuroscience Centre, University Health Network /
University Professor and Chairman of Neurosurgery, University of Toronto
Professor Nobutaka Hattori
Chairman and Professor of Neurology, and Dean of Faculty of Medicine, Juntendo University Tokyo
Malú Gámez Tansey, PhD
Director of the Center for Translational Research in Neuro-degenerative Disease (CTRND) / Norman and Susan Fixel Chair in Neuroscience and Neurology, University of Florida
Professor J. William Langston
Clinical Professor, Department of Neurology & Neurological Sciences, Stanford University
Leonard Post, PhD
Chief Scientific Officer, Vivace Therapeutics and Virtuoso Therapeutics
Eugene M. Johnson, Jr., PhD
Professor Emeritus, Neurology and Developmental Biology, Washington University Medical School, St. Louis, Missouri